FDA Investigator Haoheng Yan, PhD
Haoheng Yan, PhD has conducted inspections on 3 sites in 3 countries as of 02 Mar 2021. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
3
Last Inspection Date:
02 Mar 2021
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
Singapore,
Korea (Republic of),
United States of America
FDA Investigators that have inspected at least one site in common with Haoheng Yan, PhD:
Adam R Cooke,
Aimee Cunningham, PhD,
Anastasia M Shields,
Arie C Menachem,
Ashar P Parikh,
Bazarragchaa Damdinsuren, PhD,
Bo Chi, PhD,
Brooke K Higgins,
Chiang Syin, PhD,
Concepcion Cruz, Jr,
Diane L Raccasi,
Dianne S Alexander,
Dr. Ralph M Bernstein, PhD,
Dr. Zhihao Qiu (Peter), PhD,
Emest F Bizjak,
Erin L Mcfiren,
Hao Kiet D Phan,
Howard Anderson, PhD,
Hyung Yul Lee,
Jacek Cieslak, PhD,
Jacqueline Mdiaz Albertini,
Jennifer M Gogley,
Jennifer Swisher, PhD,
Jonathan W Chapman,
Junho Pak,
Justin A Boyd,
Kalavati Suvarna, PhD,
Kristin M Abaonza,
Kurt A Brorson, PhD,
Li Lu, PhD,
Maria Joselopez Barragan, PhD,
Matthew B Casale,
Nebil A Oumer,
Omotunde O Osunsanmi,
Patricia F Hughes, PhD,
Peter Adams, PhD,
Qin Xu,
Reyes Candau Chacon, PhD,
Richard Ledwidge (nmi), PhD,
Richard W Thornton,
Riley C Myers, PhD,
Roger F Zabinski,
Rose Ashley,
Saleem A Akhtar,
Scott N Lim,
Sena G Dissmeyer,
Steven Fong, MS, PhD,
Steven Kozlowski, MD,
Steven P Donald,
Stuart W Russell,
Thuy T Nguyen, LCDR,
Viviana Matta,
Wayne E Seifert,
Xu Michael Di, PhD,
Yasamin Ameri,
Zhao Wang, PhD,
Zhong Li, PhD
Haoheng Yan, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| August, 2018 | FDA 483 | CELLTRION Inc - Form 483, 2018-08-28 |
| August, 2018 | EIR | CELLTRION Inc - EIR, 2018-08-28 |
| March, 2021 | FDA 483 Response | AstraZeneca Pharmaceuticals LP - Form 483R, 2021-04-08 |
| March, 2021 | FDA 483 | AstraZeneca Pharmaceuticals LP - Form 483, 2021-03-19 |
| January, 2017 | FDA 483 | Amgen Singapore Manufacturing Pte. Ltd. - Form 483, 2017-01-27 |
| March, 2021 | EIR | AstraZeneca Pharmaceuticals LP - EIR, 2021-03-19 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more